<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nevirapine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nevirapine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nevirapine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9694" href="/d/html/9694.html" rel="external">see "Nevirapine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10905" href="/d/html/10905.html" rel="external">see "Nevirapine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709170"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, life-threatening, and, in some cases, fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with nonspecific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Female gender and higher CD4<sup>+</sup> cell counts at initiation of therapy place patients at increased risk; women with CD4<sup>+</sup> cell counts greater than 250 cells/mm<sup>3</sup>, including pregnant women receiving nevirapine in combination with other antiretrovirals for treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, at all CD4<sup>+</sup> cell counts, and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for postexposure prophylaxis. Use of nevirapine for occupational and nonoccupational postexposure prophylaxis is contraindicated. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Skin reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. Check transaminase levels immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine 200 mg immediate release daily dosing has been observed to decrease the incidence of rash and must be followed.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Monitoring for hepatotoxicity and skin reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these reactions. Do not restart nevirapine following clinical hepatitis, transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F200898"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Viramune XR [DSC];</li>
<li>Viramune [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867670"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Nevirapine XR [DSC];</li>
<li>Auro-Nevirapine;</li>
<li>JAMP Nevirapine;</li>
<li>MYLAN-Nevirapine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054342"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462517"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Although lead-in dosing for nevirapine therapy initiation is recommended in pediatric patients ≥2 years of age to allow for enzymatic autoinduction and reduce the occurrence of rash, it is not necessary in neonates (HHS [pediatric] 2023; HHS [perinatal] 2023).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment </b>(HHS [pediatric] 2023; HHS [perinatal] 2023): Limited data available in ages &lt;15 days: <b>Note:</b> Use in combination with other antiretroviral (ARV) agents. Adjust dose throughout course as needed based on PNA. Evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BIyhFr5DXQKXVpJHU7OxLdGQQvaV8jFf9fv%2F8URENCOd&amp;TOPIC_ID=12961" target="_blank">https://hivdb.stanford.edu</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">GA 32 to &lt;34 weeks: <i>Immediate release: </i></p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;2 weeks: Oral: 2 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 2 to &lt;4 weeks: Oral: 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 4 to 6 weeks: Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;6 weeks: Oral: 200 mg/m<sup>2</sup>/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">GA 34 to &lt;37 weeks: <i>Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;1 week: Oral: 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 1 week to 4 weeks: Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;4 weeks: Oral: 200 mg/m<sup>2</sup>/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">GA ≥37 weeks: <i>Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≤4 weeks: Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &gt;4 weeks: Oral: 200 mg/m<sup>2</sup>/dose twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b391164b-a66b-4453-92e8-bcca5447d582">HIV-1 perinatal transmission, presumptive treatment; high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 perinatal transmission, presumptive treatment; high risk (3-drug regimen): </b>Limited data available (HHS [perinatal] 2023):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Therapy should be initiated as soon as possible after birth (within 6 to 12 hours after delivery). Adjust dose throughout course as needed based on PNA; if HIV infection is confirmed in the neonate, transition to a treatment and monitoring regimen for confirmed infection. Nevirapine is recommended as part of a 3-drug regimen for empiric treatment of HIV in neonates at high risk of perinatal transmission and also serves as HIV prophylaxis; see guidelines for additional information on high-risk definition. The full 3-drug regimen may be continued for 2 to 6 weeks depending on nucleic acid test (NAT) results, maternal viral load at delivery, and additional risk factors for HIV transmission; zidovudine should be continued for the 6 weeks even if the other 2 drugs are discontinued sooner (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">GA 32 to &lt;34 weeks: <i>Immediate release: </i></p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;2 weeks: Oral: 2 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 2 to &lt;4 weeks: Oral: 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 4 to 6 weeks: Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">GA 34 to &lt;37 weeks: <i>Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;1 week: Oral: 4 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">PNA 1 to 6 weeks: Oral: 6 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">GA ≥37 weeks: <i>Immediate release:</i> Oral: 6 mg/kg/dose twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9170de04-0c39-4bbe-b71f-c813552bdf51">HIV-1 perinatal transmission, prophylaxis; high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 perinatal transmission, prophylaxis; high risk (2-drug regimen):</b> Limited data available (HHS [perinatal] 2023):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A 3-drug presumptive treatment regimen is recommended for neonates at high risk for HIV acquisition; however, a 2-drug prophylaxis regimen consisting of zidovudine in combination with prophylaxis dose of nevirapine may be considered in rare situations in consultation with a pediatric HIV expert, after an assessment of risks and benefits. Prophylaxis should begin as soon as possible after birth (within 6 to 12 hours after delivery). If HIV infection is confirmed in the neonate, discontinue prophylaxis dosing and transition to a treatment regimen and monitoring (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neonates ≥32 weeks GA: Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose (prophylaxis):</p>
<p style="text-indent:-2em;margin-left:8em;">Birthweight 1.5 to 2 kg: Oral: <b>8 mg</b> for 3 doses: Administer the first dose as soon as possible after birth (within 48 hours), the second dose 48 hours after the first, and the third dose 96 hours after the second.</p>
<p style="text-indent:-2em;margin-left:8em;">Birthweight &gt;2 kg: Oral: <b>12 mg</b> for 3 doses: Administer the first dose as soon as possible after birth (within 48 hours), the second dose 48 hours after the first, and the third dose 96 hours after the second.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e56e2cb7-474c-4e3f-b782-45e214b71f4e">HIV-1 transmission during breastfeeding; prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 transmission during breastfeeding; prophylaxis: </b>Limited data available; optimal antiretroviral choice and duration are unclear, and expert recommendations vary:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Shared decision making should be utilized regarding infant feeding options, with considerations of risks, benefits, and personal preferences; breastfeeding is recommended only for individuals who are receiving antiretroviral therapy and have sustained viral suppression; neonates at high risk of transmission should complete a presumptive treatment regimen and negative infant nucleic acid test (NAT) should be verified prior to prophylaxis. Dosing provided is a simplified, fixed-dose regimen (not weight-based). See guidelines for details (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates ≥32 weeks GA: <i>Immediate release</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">PNA &lt;6 weeks: Oral: 15 <b>mg</b> daily (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">PNA ≥6 weeks: 20 <b>mg</b> daily (HHS [perinatal] 2023).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F200921"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Note: </b>Use in combination with other antiretroviral (ARV) agents; evaluate gene mutation and ARV resistance patterns (refer to https://www.iasusa.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BIyhFr5DXQKXVpJHU7OxLdGQQvaV8jFf9fv%2F8URENCOd&amp;TOPIC_ID=12961" target="_blank">https://hivdb.stanford.edu</a> for more information).</p>
<p style="text-indent:-2em;margin-left:4em;">Although lead-in dosing recommended in pediatric patients ≥2 years of age when initiating therapy to allow for enzymatic autoinduction and reduce the occurrence of rash, it may not be necessary in infants and children &lt;2 years of age (HHS [pediatric] 2023). If patient experiences a nonsevere rash (in the absence of transaminase elevations) during the first 14 days of therapy, do not increase dose until rash has resolved. If rash continues beyond 28 days, use an alternative regimen. Discontinue nevirapine if severe rash, rash with constitutional symptoms, or rash with elevated hepatic transaminases occurs. If nevirapine therapy is interrupted for ≤14 days (infants/children) or ≤7 days (adolescents), restart at the full dose due to mechanisms of nevirapine resistance, half-life of CYP enzymes, and clinical trial results (HHS [adult] 2023; HHS [pediatric] 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release</i> (HHS [pediatric] 2023):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;2 years:</p>
<p style="text-indent:-2em;margin-left:10em;">With lead-in dosing: Oral: Initial: 200 mg/m<sup>2</sup>/dose once daily (maximum dose: 200 mg/dose) for the first 14 days of therapy, then increase to 200 mg/m<sup>2</sup>/dose twice daily (maximum dose: 200 mg/dose) if no rash or other adverse effects occur.</p>
<p style="text-indent:-2em;margin-left:10em;">Without lead-in dosing: Oral: 200 mg/m<sup>2</sup>/dose twice daily (maximum dose: 200 mg/dose); monitor patients for tolerability (eg, rash).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;8 years: Oral: Initial (lead-in dosing): 200 mg/m<sup>2</sup>/dose once daily (maximum dose: 200 mg/dose) for the first 14 days of therapy, then increase to 200 mg/m<sup>2</sup>/dose twice daily (maximum dose: 200 mg/dose) if no rash or other adverse effects occur.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥8 years: Oral: Initial (lead-in dosing): 120 to 150 mg/m<sup>2</sup>/dose once daily (maximum dose: 200 mg/dose) for the first 14 days of therapy, then increase to 120 to 150 mg/m<sup>2</sup>/dose twice daily (maximum dose: 200 mg/dose) if no rash or other adverse effects occur. <b>Note:</b> In a growing child, do not decrease the mg dose when the child reaches 8 years; leave the mg dose the same to achieve the appropriate mg/m<sup>2</sup>/dose as the child grows larger (as long as there are no adverse effects).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: Initial: 200 mg once daily for the first 14 days, then increase to 200 mg every 12 hours if no rash or other adverse effects occur; if patient able to swallow tablets whole, may convert maintenance dose to the extended-release formulation (400 mg once daily).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release</i> (HHS [pediatric] 2023): <b>Note:</b> For patients established on full-dose nevirapine, may initiate extended-release preparation without lead-in dosing. If initiating nevirapine therapy, begin with the age-appropriate once-daily dose of the <i>immediate-release formulation</i> for the first 14 days of therapy; at 14 days, if no rash or other adverse effects have occurred, increase dose to the age-appropriate dose administered once daily of the extended-release formulation. Extended-release tablets should not be divided to achieve daily dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years: Must be able to swallow tablets whole: BSA-directed dosing (HHS [pediatric] 2023):</p>
<p style="text-indent:-2em;margin-left:10em;">BSA 0.58 to 0.83 m<sup>2</sup>: Oral: 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA 0.84 to 1.16 m<sup>2</sup>: Oral: 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥1.17 m<sup>2</sup>: Oral: 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 400 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e56e2cb7-474c-4e3f-b782-45e214b71f4e">HIV-1 transmission during breastfeeding; prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 transmission during breastfeeding; prophylaxis: </b>Limited data available; Optimal antiretroviral choice and duration are unclear, and expert recommendations vary:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Shared decision making should be utilized regarding infant feeding options, with considerations of risks, benefits, and personal preferences; breastfeeding is recommended only for individuals who are receiving antiretroviral therapy and have sustained viral suppression; neonates at high risk of transmission should receive a presumptive treatment regimen and negative infant nucleic acid test (NAT) should be verified prior to prophylaxis. Dosing provided is a simplified, fixed-dose regimen (not weight-based). See guidelines for details (HHS [perinatal] 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants (HHS [perinatal] 2023): <i>Immediate release:</i></p>
<p style="text-indent:-2em;margin-left:6em;">6 weeks to &lt;6 months: Oral: 20 <b>mg</b> daily.</p>
<p style="text-indent:-2em;margin-left:6em;">6 months to &lt;9 months: Oral: 30 <b>mg</b> daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥9 months: Oral: 40<b> mg</b> daily. <b>Note: </b>Continue through 1 to 4 weeks after weaning.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130776"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥20 mL/minute: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: An additional dose of nevirapine should be given following dialysis (HHS [pediatric] 2023). <b>Note:</b> Nevirapine metabolites may accumulate in patients on dialysis (clinical significance is unknown).</p></div>
<div class="block dohp drugH1Div" id="F51130777"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments provided in manufacturer's labeling; use with caution; monitor for symptoms of drug-induced toxicity (increased trough concentrations have been observed in some patients with hepatic fibrosis or cirrhosis).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use is contraindicated; permanently discontinue if symptomatic hepatic events occur or if any severe transaminase elevations are observed (HHS [pediatric] 2023; manufacturer's labeling).</p></div>
<div class="block doa drugH1Div" id="F200903"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9694" href="/d/html/9694.html" rel="external">see "Nevirapine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Nevirapine should not be initiated in antiretroviral-naive patients with elevated CD4<sup>+</sup>-cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4<sup>+</sup>-cell counts &gt;250 cells/mm<sup>3</sup>; adult males: CD4<sup>+</sup>-cell counts &gt;400 cells/mm<sup>3</sup>). Nevirapine is not recommended as a component of initial therapy for the treatment of adults with HIV (HHS [adult] 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 200 mg immediate-release nevirapine once daily for 14 days, followed by 200 mg immediate-release nevirapine twice daily <b>or</b> 400 mg extended-release nevirapine once daily. Use as part of an appropriate combination regimen. <b>Note:</b> If patient experiences a nonsevere rash (without constitutional symptoms) during the 14-day lead-in period with 200 mg/day, do not increase to maintenance dosage until the rash has resolved. If rash continues beyond 28 days on the 200 mg/day dose, use an alternative regimen. The lead-in period must always be done with IR formulation. If therapy with any formulation is interrupted for &gt;7 days, restart with initial dose of IR formulation for 14 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991403"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: No dosage adjustment necessary for any degree of renal impairment (HHS [adult] 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: An additional 200 mg <i>immediate release</i> dose is recommended following dialysis.</p></div>
<div class="block doha drugH1Div" id="F50988622"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Permanently discontinue if symptomatic hepatic events occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary (HHS [adult] 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F200865"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum cholesterol (3% to 19%), increased LDL cholesterol (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased serum phosphate (≤38%), neutropenia (1% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (2% to 5%), headache (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4% to 7%; children: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased amylase (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 9%), abdominal pain (2% to 3%), diarrhea (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (2% to 9%), increased serum transaminases (asymptomatic; &gt;5x ULN: 6%), hepatic disease (4%), hepatitis (2% to 4%; may be hypersensitivity related)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous maculopapular rash, pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal transaminase, anaphylaxis, anemia, angioedema, aphthous stomatitis, autoimmune disease, bullous rash, cholestatic hepatitis, conjunctivitis, DRESS syndrome, drowsiness, drug withdrawal, eosinophilia, facial edema, flu-like symptoms, fulminant hepatitis, Graves disease, Guillain-Barre syndrome, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatomegaly, hepatotoxicity, hyperbilirubinemia, hypersensitivity reaction, immune reconstitution syndrome, jaundice, lipotrophy, liver tenderness, lymphadenopathy, malaise, myalgia, oral lesion, paresthesia, polymyositis, prolonged partial thromboplastin time, redistribution of body fat, renal insufficiency, rhabdomyolysis, skin blister, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, vomiting</p></div>
<div class="block coi drugH1Div" id="F200880"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe hepatic impairment (Child-Pugh class B or C); use in occupational or nonoccupational postexposure prophylaxis (PEP) regimens</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Clinically significant hypersensitivity to nevirapine or any component of the formulation; therapy rechallenge in patients with prior hypersensitivity reactions, severe rash, rash accompanied by constitutional symptoms, or clinical hepatitis due to nevirapine; severe hepatic dysfunction or AST or ALT &gt;5 times ULN (pretreatment or during prior use of nevirapine); hereditary conditions of galactose intolerance (eg, galactosemia, congenital lactase deficiency, glucose-galactose malabsorption); concomitant use of herbal products containing St John's wort</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F200862"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fat redistribution: May cause redistribution/accumulation of fat (eg, central obesity, buffalo hump, peripheral wasting, facial wasting, breast enlargement, cushingoid appearance).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome, resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Has been observed in conjunction with skin and/or hepatic adverse events. Discontinuation of therapy is warranted with evidence of severe skin or liver toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Patients with a history of chronic hepatitis (B or C) or increased baseline transaminase levels may be at increased risk of later symptomatic hepatotoxic events (≥6 weeks after treatment initiation) and asymptomatic increases in AST or ALT. Use with caution in patients with preexisting dysfunction; monitor closely for drug-induced hepatotoxicity. Use is contraindicated in patients with moderate to severe impairment (Child-Pugh class B or C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Prednisone: Coadministration of prednisone during the first 6 weeks of therapy increases incidence and severity of rash; concomitant prednisone is not recommended to prevent rash.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: When initiating therapy, a 14-day lead-in dose with the immediate release formulation should be used to decrease risk of skin reactions. If rash appears during the 14-day lead-in period, do not increase the dose or initiate the extended release formulation until the rash has resolved. An alternative regimen should be used if the lead-in dose period exceeds 28 days. Therapy in antiretroviral naive patients should not be initiated in patients with elevated CD4<sup>+</sup>-cell counts unless the benefit of therapy outweighs the risk of serious hepatotoxicity (adult/postpubertal females: CD4<sup>+</sup>-cell counts &gt;250 cells/mm<sup>3</sup>; adult males: CD4<sup>+</sup>-cell counts &gt;400 cells/mm<sup>3</sup>). If CD4<sup>+</sup>-cell counts increase above these thresholds as a result of nevirapine-containing therapy, therapy may be continued. After the lead-in period, patients may be switched to the extended-release formulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Resistance: Due to rapid emergence of resistance, nevirapine should not be used as monotherapy or the only agent added to a failing regimen for the treatment of HIV. When discontinuing an antiretroviral regimen containing nevirapine, take into account the long half-life of nevirapine. If other agents with shorter half-lives are stopped concurrently, low nevirapine plasma concentrations may persist for a week or longer and virus resistance may subsequently develop.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878562"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The incidence of rash in pediatric patients is 21% (manufacturer's labeling); in children, a 3-fold increased risk of rash and hepatotoxicity has been observed when nevirapine is initiated with a CD4 &gt;15% (HHS [pediatric] 2023). Granulocytopenia may occur; it is more common in neonates and young infants (2 weeks to &lt;3 months of age) compared to older children and adults and also more common in pediatric patients receiving concomitant zidovudine. Anemia occurred in 7% of pediatric clinical trial patients; it has been reported more commonly in children in postmarketing reports, but effects of concomitant medications cannot be separated out.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse cardiac effects have been associated with nevirapine therapy in both pediatric and adult patients (HHS [pediatric] 2023). A prospective study of 325 pediatric patients aged 7 to 16 years with perinatally acquired HIV evaluated associations between previous or current antiretroviral agents and cardiac echocardiogram measures. When comparing patients currently receiving nevirapine (n=18) with those who were not, nevirapine therapy was associated with higher left ventricular end-diastolic dimension (Williams 2018). Similarly, a cross-sectional study of pediatric subjects 6 to 16 years of age (n=201) receiving antiretroviral therapy for ≥6 months (median duration: 4.7 years) demonstrated an association between current use of nevirapine (n=103) and left ventricular hypertrophy (adjusted odds ratio: 3.14, <i>P</i>=0.03) (Majonga 2018). However, in an 18-month prospective follow-up of 197 of the previously described patients, no specific antiretroviral agent was associated with echocardiographic abnormalities (nevirapine receipt, n=61) (Majonga 2020). Implications for cardiac outcomes later in life (eg, cardiomyopathy) are unknown (Williams 2018).</p></div>
<div class="block foc drugH1Div" id="F200874"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viramune: 50 mg/5 mL (240 mL [DSC]) [contains methylparaben, polysorbate 80, propylparaben, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (240 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viramune: 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Viramune XR: 400 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg [DSC], 400 mg</p></div>
<div class="block geq drugH1Div" id="F200858"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F200883"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Nevirapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Nevirapine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $19.83 - $23.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nevirapine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $10.80 - $10.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867671"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg [DSC]</p></div>
<div class="block admp drugH1Div" id="F52613412"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Oral suspension: Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especially if the dose is &lt;5 mL; if using a dosing cup, after administration rinse cup with water and also administer rinse.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Swallow tablet whole; do not chew, crush, or divide.</p></div>
<div class="block adm drugH1Div" id="F200877"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food. Shake suspension gently prior to administration; the use of an oral dosing syringe is recommended, especially if the dose is ≤5 mL; if using a dosing cup, after administration, rinse cup with water and also administer rinse. ER tablets must be swallowed whole and not crushed, chewed, or divided.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet and oral suspension formulations are available. If safety and efficacy of nevirapine can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, therapeutic drug monitoring and/or viral load monitoring is recommended in the short-term postoperative period (ie, 10 to 14 days) and at regular follow-up intervals after bariatric surgery to validate drug absorption that may change with small bowel adaption or transit over time.</p></div>
<div class="block hazard drugH1Div" id="F49132873"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>
<div class="block sts drugH1Div" id="F3099313"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F7874746"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F201152s014lbl.pdf%23page%3D18&amp;token=yGcpKxP6pmHFbx9SHOqekDwXQpwr9X548YoDOALVOM7kBD4Wt0PPq5kVYS2yWagGSaZ6axTIAzIHJ2n5U8MUxc%2FstlnpRsEL%2BhFM6XVKYCmA7CPlPeM9AZucJWo9V4bL&amp;TOPIC_ID=12961" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201152s014lbl.pdf#page=18</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53568000"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (Immediate release: FDA approved in ages ≥15 days and adults; Extended release: FDA approved in ages ≥6 years with a BSA ≥1.17 m<sup>2</sup> and adults). <b>Note:</b> HIV regimens consisting of <b>three</b> active antiretroviral agents from at least <b>two</b> classes are recommended. Not recommended to be initiated in adult females with CD4+ counts &gt;250 cells/mm<sup>3</sup> or in adult males with CD4+ counts &gt;400 cells/mm<sup>3</sup> unless the benefit outweighs the risk. Nevirapine has also been used in prevention of perinatal HIV transmission.</p></div>
<div class="block mst drugH1Div" id="F200943"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nevirapine may be confused with nelfinavir</p>
<p style="text-indent:-2em;margin-left:4em;">Viramune, Viramune XR may be confused with Viracept, Viramune (herbal product)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F200929"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> MRP2; <b>Induces</b> CYP2B6 (moderate), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F200867"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: Nevirapine may decrease the serum concentration of Amodiaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Nevirapine may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. Nevirapine may decrease the serum concentration of Artemether and Lumefantrine. Nevirapine may increase the serum concentration of Artemether and Lumefantrine. Specifically, lumefantrine concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: Nevirapine may decrease serum concentrations of the active metabolite(s) of Artesunate. Nevirapine may increase the serum concentration of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Moderate) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Nevirapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: Nevirapine may increase serum concentrations of the active metabolite(s) of Clarithromycin. Nevirapine may decrease the serum concentration of Clarithromycin.  Management: Consider alternatives to clarithromycin, such as azithromycin, for the treatment of <i>Mycobacterium avium-intracellulare complex</i> in patients taking nevirapine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: CYP2B6 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of CycloPHOSphamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Nevirapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Nevirapine. Management: Consider alternatives to this combination when possible. If combined, monitor for reduced nevirapine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: Nevirapine may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with nevirapine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May increase the serum concentration of Nevirapine. Nevirapine may increase the serum concentration of Darunavir. Management: Avoid coadministration of darunavir/cobicistat and nevirapine. No action is required if darunavir/ritonavir is combined with nevirapine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Nevirapine may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Nevirapine may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estriol (Systemic): Nevirapine may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estriol (Topical): Nevirapine may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Nevirapine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Nevirapine may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may increase the serum concentration of Nevirapine.  Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Nevirapine may decrease the serum concentration of Indinavir.  Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Nevirapine may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Nevirapine may decrease the serum concentration of Ketoconazole (Systemic).  Management: Avoid use of nevirapine in the 2 weeks prior to and during ketoconazole therapy unless benefits outweigh the risk of diminished ketoconazole efficacy. Monitor ketoconazole efficacy and consider dose increases if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: Nevirapine may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Nevirapine may diminish the therapeutic effect of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Nevirapine may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Levomethadone.  Management: Levomethadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: Nevirapine may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with nevirapine.  Avoid use of this combination in patients less than 6 months of age. Lopinavir/ritonavir dose adjustments are required for patients taking twice daily lopinavir/ritonavir. See full monograph.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP2B6 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP2B6 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Nevirapine may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Nevirapine may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reverse Transcriptase Inhibitors (Non-Nucleoside): May enhance the adverse/toxic effect of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, efavirenz and nevirapine may decrease the serum concentrations of other non-nucleoside reverse transcriptase inhibitors. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, delavirdine may increase the serum concentration of etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: Nevirapine may increase serum concentrations of the active metabolite(s) of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Nevirapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Nevirapine may decrease the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Nevirapine may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: Nevirapine may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Nevirapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Nevirapine may decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Nevirapine may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308492"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Contraception is not required to initiate or continue antiretroviral therapy.</p>
<p style="text-indent:0em;margin-top:2em;">The US Department of Health and Human Services (HHS) perinatal HIV guidelines do not recommend nevirapine (except in special circumstances) in patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F200884"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nevirapine has a high level of transfer across the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">No increased risk of overall teratogenic effects following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes including preterm birth, low birth weight, and small-for-gestational-age infants. Actual risks may be influenced by maternal factors such as disease severity, GA at initiation of therapy, and specific ART regimen, therefore close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. Female gender and higher CD4+ cell counts at initiation of therapy place patients at increased risk; females with CD4+ cell counts &gt;250 cells/mm<sup>3</sup>, including patients who are pregnant receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. Intensive monitoring must be done during the first 18 weeks of nevirapine therapy with extra vigilance during the first 6 weeks, which is the period of greatest risk of hepatotoxicity and skin reactions.</p>
<p style="text-indent:0em;margin-top:2em;">The US Department of Health and Human Services (HHS) perinatal HIV guidelines do not recommend nevirapine as an initial non-nucleoside reverse transcriptase inhibitor for use in antiretroviral-naive pregnant patients because of the potential for adverse events, complex dosing, and low barrier to resistance. Use is not recommended (except in special circumstances) in pregnant patients with HIV who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant while taking nevirapine may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">Pharmacokinetics of the IR formulation are not significantly altered during pregnancy; dose adjustment is not currently recommended (data not available for ER formulation).</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender-diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block mopp drugH1Div" id="F53568001"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=12961" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral drug-resistance testing is recommended before initiation of therapy in treatment-naive patients and before changing regimens in patients for whom therapy has failed. After initiation of or change in antiretroviral therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">CD4 percentage (prior to initiation); lipid profiles (baseline and periodically with therapy), AST and ALT (baseline, at 2 and 4 weeks, and every 3 months). Monitor for rash and signs/symptoms of hepatitis.</p></div>
<div class="block rerp drugH1Div" id="F53567842"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Plasma trough concentration ≥3 to 4 mcg/mL (Gopalan 2017; Punyawudho 2016)</p></div>
<div class="block pha drugH1Div" id="F200861"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a non-nucleoside reverse transcriptase inhibitor, nevirapine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.</p></div>
<div class="block phk drugH1Div" id="F200879"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid and readily absorbed; Immediate release: &gt;90%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely; V<sub>d</sub>: 1.2 L/kg; CSF penetration approximates 40% to 50% of plasma</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding, plasma: ~60%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic via CYP3A4 and CYP2B6 (hydroxylation to inactive compounds); may undergo enterohepatic recycling; nevirapine is more rapidly metabolized in pediatric patients than in adults </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 93% (immediate release tablet); ~75% (extended release tablet [relative to immediate release]); 91% (oral solution) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Decreases over 2- to 4-week time with chronic dosing due to autoinduction (ie, half-life = 45 hours initially [single dose] and decreases to 25 to 30 hours [multiple dosing])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release: 4 hours; Extended release:~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~81%, primarily as metabolites, &lt;3% as unchanged drug); feces (~10%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Women have a 13.8% lower clearance compared to men; body size does not totally explain the gender difference</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F200886"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Filide | Nerapin | Nevirapina | Ritvir | Viramune</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nevirapin accord | Nevirapin mylan | Nevirapin Sandoz | Viramune</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nevipin | Nevirapine Alphapharm | Nevirapine Rbx | Nevirapine xr apotex | Viramune</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine mylan | Nevirapine sandoz | Viramune</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Neviparine | Viramune</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Farmanguinhos nevirapina | Viramune</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nevirapin mepha | Nevirapin mylan | Nevirapin sandoz retard | Viramune</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Nevek | Nevihope | Nevivir</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nevurit | Viramune | Virap</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai tai | Nuo lan pin | Viramune</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciplanevimune | Evirapin | Godapaus | Nevipan | Neviparina | Nevirapina | Nevivir | Niverin | Viramune | Viravir</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nevirapin accord | Nevirapin Aurobindo | Nevirapin axiromed | Nevirapin beta | Nevirapin Hexal | Nevirapin hormosan | Nevirapin mylan | Nevirapin ratiopharm | Nevirapin teva | Nevirapine Heumann | Viramune</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nevirapina accord | Nevirapina actavis | Nevirapina aurobindo | Nevirapina aurovitas | Nevirapina combino pharm | Nevirapina kern pharma | Nevirapina mylan | Nevirapina normon | Nevirapina Sandoz | Nevirapina tarbis farma | Nevirapina Teva | Viramune</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine accord | Nevirapine mylan | Viramune</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine arrow lab | Nevirapine Cristers | Nevirapine cristers LP | Nevirapine mylan | Nevirapine mylan LP | Nevirapine sandoz | Nevirapine sandoz lp | Nevirapine teva | Viramune</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine Dr. reddy's | Nevirapine milpharm | Nevirapine mylan | Nevirapine teva | Viramune</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine vocate | Viramune</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine Hspt | Nevirapine teva | Nevita | Viramune</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Neviral</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Neve | Nevihope | Nevimat | Nevimune | Nevipan | Nevir | Neviretro | Nevirex | Nevivir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nevirapina | Nevirapina accord | Nevirapina aurobindo | Nevirapina mylan | Nevirapina Sandoz | Nevirapina teva italia | Viramune</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aspen nevirapine | Nevimune | Nevipan | Nevir | Neviriv | Nevivir | Viramune</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Nevimune | Viramune</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nevimune | Nevirapin accord | Nevirapin hormosan | Viramune</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nevirapin | Viramune</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nebriprim | Pyari | Viramune</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hirapine | Nevipan | Viramune</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Nevidek | Nevivir | Nevran | Tyonex nevirapine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine accord | Nevirapine aurobindo | Nevirapine mylan | Nevirapine retard teva | Nevirapine sandoz | Viramune</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine Alphapharm | Nevirapine viatris | Viramune</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Nevirapina</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Nevimat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine accord | Nevirapine mylan | Viramune</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nevirapina accord | Nevirapina aurovitas | Nevirapina farmoz | Nevirapina Generis | Nevirapina mylan | Nevirapina Sandoz | Nevirapina Teva | Viramune</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Nevimune | Protease | Viramune</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Nevirapina accord | Nevirapina Teva | Viramune</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine tl | Nevirpine | Viramune</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nevirapin 2care4 | Nevirapin ebb | Nevirapine Medical Valley | Nevirapine mylan | Nevirapine teva b.v. | Viramune</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Neravir | Viramune</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Viramune</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nevimat | Viramune | Viramune xr</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nevirapine aurobindo | Nevirapine mylan | Nevivir</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Nevimune | Nevivir | Viramune</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Nevihope | Nevimune | Viramune</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Filide | Neviralea | Nevirapina | Protease | Viramune</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acriptaz | Adco Nevirapine | Aspen nevirapine | Auro nevirapine | Bindopin | Cipla nevirapine | Nevimune | Nevir | Nevivir | Nevran | Sonke nevirapine | Vari nevirapine | Viramune</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aspen nevirapine | Nevimune | Nevipan | Nevirex | Nevivir | Okamune | Viramune</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Nevimat | Nevimune | Nevipan | Nevivir</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Auro-Nevirapine (nevirapine) [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8633815">
<a name="8633815"></a>D'Aquila RT, Hughes MD, Johnson VA, et al, “Nevirapine, Zidovudine, and Didanosine Compared With Zidovudine and Didanosine in Patients With HIV-1 Infection. A Randomized, Double-Blind, Placebo-Controlled Trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators,” <i>Ann Intern Med</i>, 1996, 124(12):1019-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/8633815/pubmed" id="8633815" target="_blank">8633815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827836">
<a name="28827836"></a>Gopalan BP, Mehta K, D'souza RR, et al. Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. <i>PLoS One</i>. 2017;12(8):e0183080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/28827836/pubmed" id="28827836" target="_blank">28827836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8263750">
<a name="8263750"></a>Hammer SM, Kessler HA, and Saag MS, “Issues in Combination Antiretroviral Therapy: A Review,” <i>J Acquir Immune Defic Syndr</i>, 1994, 7(Suppl 2):24-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/8263750/pubmed" id="8263750" target="_blank">8263750</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Havlir DV and Lange JM, “New Antiretrovirals and New Combinations,” <i>AIDS</i>, 1998, 12(Suppl A):165-74.</div>
</li>
<li>
<div class="reference">
                  HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated December 18, 2019. Accessed December 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9853641">
<a name="9853641"></a>Hilts AE and Fish DN, “Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,” <i>Am J Health Syst Pharm</i>, 1998, 55:2528-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/9853641/pubmed" id="9853641" target="_blank">9853641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917901">
<a name="23917901"></a>Kuhar DT, Henderson DK, Struble KA, et al, "Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis," <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/23917901/pubmed" id="23917901" target="_blank">23917901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31054255">
<a name="31054255"></a>Majonga ED, Rehman AM, Mchugh G, et al. Incidence and progression of echocardiographic abnormalities in older children with human immunodeficiency virus and adolescents taking antiretroviral therapy: a prospective cohort study. <i>Clin Infect Dis</i>. 2020;70(7):1372‐1378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/31054255/pubmed" id="31054255" target="_blank">31054255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30289814">
<a name="30289814"></a>Majonga ED, Rehman AM, Simms V, et al. High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. <i>AIDS</i>. 2018;32(18):2739‐2748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/30289814/pubmed" id="30289814" target="_blank">30289814</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nevirapine extended-release tablet [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; August 2022.</div>
</li>
<li>
<div class="reference">
                  Nevirapine extended-release tablet [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; November 2018.</div>
</li>
<li>
<div class="reference">
                  Nevirapine oral suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; July 2022.</div>
</li>
<li>
<div class="reference">
                  Nevirapine tablet [prescribing information]. Princeton, NJ: Macleods Pharma USA; July 2022.</div>
</li>
<li>
<div class="reference">
                  Public Health Agency of Canada (PHAC). Canadian guidelines on sexually transmitted infection. Available at <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html" target="_blank">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines.html</a>. Last modified December 2013. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27626677">
<a name="27626677"></a>Punyawudho B, Singkham N, Thammajaruk N, et al. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. <i>Expert Rev Clin Pharmacol</i>. 2016;9(12):1583-1595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/27626677/pubmed" id="27626677" target="_blank">27626677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated January 2022. Accessed August 3, 2022.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated March 2023. Accessed July 10, 2023.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new</a>. Updated April 11, 2023. Accessed July 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed July 10, 2023.</div>
</li>
<li>
<div class="reference">
                  Viramune (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; June 2022.</div>
</li>
<li>
<div class="reference">
                  Viramune XR (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9708401">
<a name="9708401"></a>Weverling GJ, Lange JM, Jurriaans S, et al, “Alternative Multidrug Regimen Provides Improved Suppression of HIV-1 Replication Over Triple Therapy,” <i>AIDS</i>, 1998, 12(11):F117-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/9708401/pubmed" id="9708401" target="_blank">9708401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30102660">
<a name="30102660"></a>Williams PL, Correia K, Karalius B, et al. Cardiac status of perinatally HIV-infected children: assessing combination antiretroviral regimens in observational studies. <i>AIDS</i>. 2018;32(16):2337‐2346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nevirapine-pediatric-drug-information/abstract-text/30102660/pubmed" id="30102660" target="_blank">30102660</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12961 Version 392.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
